The White House recently announced new “most-favored-nation” (MFN) drug pricing agreements with nine companies, promoting them as evidence of declining drug costs. However, the details of these agreements remain opaque, lacking enforcement mechanisms or independent validation of savings for consumers. While the Trump administration attributes price decreases to these agreements, tangible results from the Inflation Reduction Act (IRA) signified real cost reductions, such as a 3.1% decline in prescription drug prices, the steepest since 1963.
The IRA’s provisions allow Medicare to negotiate drug prices and cap out-of-pocket costs for seniors, with projected savings of billions. In contrast, existing MFN agreements often do not benefit consumers using insurance. The IRA’s reforms are generating measurable savings, unlike MFN deals, which can be easily revised without accountability.
Going forward, it’s proposed that Congress increase the number of drugs eligible for negotiation, extend these prices to commercial markets, and close loopholes to encourage competition and ensure more comprehensive and sustained cost savings for patients. A value-based drug pricing approach is also encouraged, relying on rigorous assessments that reflect the actual worth of drugs in the U.S. healthcare system.
